This trial aimed to investigate the therapeutic efficacy of ruxolitinib in combination with cytotoxic chemotherapy for post-myeloproliferative neoplasm secondary acute myeloid leukemia.
Name: RuxolitinibDescription: Induction chemotherapy include combination of cytarabine (200mg/m2) and idarubicin (12mg/m2). Both 7+3 and 5+2 regimen is allowed according to age and performance status (PS) as follows; If Age < 55 years and ECOG PS < 2 : 7+3 regimen If Age ≥ 55 years or ECOG PS = 2 : 5+2 regimen Ruxolitinib is administered for 14 days during induction/consolidation phase. After complete remission after induction, ruxolitinib is administered for the first 14 days during consolidation chemotherapy. Maximum 3 cycles of consolidation is recommended. In case of allogeneic stem cell transplantation (alloSCT), ruxolitinib is discontinued at the time of transplantation. After completion of consolidation, 2 years of ruxolitinib maintenance is planned. The follow-up period is from the time of enrollment until 24 months.Type: Drug
Description: from the date of transplantation to death from any causeMeasure: Overall survival Time: 3, 6, 12, 24 months after induction chemotherapy
Description: from the date of transplantation to the date of disease progression or death from any causeMeasure: Progression-free survival Time: 3, 6, 12, 24 months after induction chemotherapy
Description: according to CTCAE version 4.03Measure: Toxicity profile Time: 3, 6, 12, 24 months after induction chemotherapy
Single Group Assignment
There is one SNP
JAK2 V617F mutation, which is a hallmark of MPN, has been reported to be carried in approximately 35-50% of patients with post-MPN AML. --- V617F ---